Kennedy Vaccine Adviser William Thompson Promoted to Oversee CDC’s Childhood Health Research
WASHINGTON — William Thompson, a vaccine adviser at the Centers for Disease Control and Prevention…
Newswire
Galux and Boehringer Ingelheim Agree to Design Purpose-Specific Protein Molecules
Galux, a South Korean biotech specializing in AI-driven protein therapeutics discovery, has entered into a…
Patient deaths put Merck, Daiichi’s ADC trial on partial hold
The FDA has imposed a partial hold on the clinical trial of I-DXd, a novel…
UnitedHealth Claims Robust Audit Findings Amid Contradictory Independent Reviews
UnitedHealth Group announced on Friday that its recent audits, conducted by hired consultants, reveal that…
White House Set to Announce Largest Batch of Drug Pricing Agreements Yet
WASHINGTON — Nine drugmakers are poised to unveil agreements with the Trump administration aimed at…
Post-Election Shifts in Health and Medicine Signal Unprecedented Changes Ahead
In a letter dated two days after the 2024 presidential election, STAT’s Rick Berke highlighted…
Galapagos’ Last Asset Posts Mixed Results as Future Remains in Flux
Galapagos has reported mixed results for its final asset, raising questions about the future direction…
Tech Mahindra Secures Multiple Awards at the 2025 Pharmaceutical Technology Excellence Awards
Tech Mahindra has been recognized with the Safety, Research and Development, and Innovation awards at…
BioMarin to Acquire Rare Disease Drugmaker Amicus for $4.8B
BioMarin Pharmaceutical has announced its acquisition of Amicus Therapeutics for $4.8 billion, a strategic move…
BioMarin to pay $4.8B for Amicus and its rare disease drugs
BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved…